Literature DB >> 19886383

Are persons living with HIV timely accessing ART services in India?

Ruchi Sogarwal1, Damodar Bachani.   

Abstract

CD4+ T-cell level is one of the important criteria for categorising HIV-related clinical conditions to determine initiation of antiretroviral therapy (ART). The present study is undertaken to analyse baseline CD4 count at which persons living with HIV/AIDS (PLHA) were getting registered for ART in India. It also examines the profile of the PLHA with baseline CD4 count over a period of time. Data of 1,10,974 registered PLHAs at ART centres were analysed for the last three years (April 2005 to March 2008) in the computerised management information system. It was revealed that 85 per cent of PLHA were registered when their baseline CD4 count was less than 250 cells/mm3 and thus were eligible for initiation of ART. No significant change in the proportion of PLHA by CD4 categories was observed in the last three years. These findings suggest that registration for ART at early stages of infection is still uncommon. Significant decline in the proportion of PLHA in the age group of 21-30 years, literate and employed was noticed. The proportion of PLHA referred by counselling and testing centres has increased from 62.6% in 2005-06 to 71.3% in 2007-08. Sexual transmission, followed by mother to child transmission has been reported as two major modes of HIV transmission by PLHA registered at ART centres in the last three years. Though the number of ART centres has increased in India which in turn has increased the number of PLHAs registered and on ART, it is evident from this study that the programme is still far behind to achieve the goal of early detection for timely ART.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19886383

Source DB:  PubMed          Journal:  J Indian Med Assoc        ISSN: 0019-5847


  7 in total

1.  Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.

Authors:  Kartik K Venkatesh; Jessica E Becker; Nagalingeswaran Kumarasamy; Yoriko M Nakamura; Kenneth H Mayer; Elena Losina; Soumya Swaminathan; Timothy P Flanigan; Rochelle P Walensky; Kenneth A Freedberg
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

2.  Scaling up antiretroviral treatment services in Karnataka, India: impact on CD4 counts of HIV-infected people.

Authors:  Suresh Shastri; Pavithra Hatna Boregowda; Bharat B Rewari; Sukarma Tanwar; Anita Shet; Ajay M V Kumar
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

3.  Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.

Authors:  Lauren M Uhler; Nagalingeswaran Kumarasamy; Kenneth H Mayer; Anjali Saxena; Elena Losina; Malaisamy Muniyandi; Adam W Stoler; Zhigang Lu; Rochelle P Walensky; Timothy P Flanigan; Melissa A Bender; Kenneth A Freedberg; Soumya Swaminathan
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

4.  Eliminating HIV & AIDS in India: A roadmap to zero new HIV infections, zero discrimination & zero AIDS-related deaths.

Authors:  Riya Palchaudhuri; Max Niggl; Clovis Steve Palmer
Journal:  Indian J Med Res       Date:  2016-12       Impact factor: 2.375

5.  Progression of CD4 count among human immunodeficiency virus-seropositive patients in a tertiary care hospital of Tripura, North East India.

Authors:  Tapan Majumdar; Niladri Sekhar Das; Ayan Modak
Journal:  Indian J Sex Transm Dis AIDS       Date:  2020-07-31

6.  The journey to antiretroviral therapy in Karnataka, India: who was lost on the road?

Authors:  Suresh Shastri; Srinath Sathyanarayna; Sharath Burugina Nagaraja; Ajay Mv Kumar; Bharat Rewari; Anthony D Harries; Rony Zachariah
Journal:  J Int AIDS Soc       Date:  2013-08-27       Impact factor: 5.396

7.  Trends in Clinical Characteristics and Short-Term Outcome of HIV-Infected Patients at a Tertiary Care Hospital in South India.

Authors:  Suryanarayana Bettadpura Shamanna; Kiran Kumar Matta; Abdoul Hamide
Journal:  J Int Assoc Provid AIDS Care       Date:  2018 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.